After Aetna Inc. and Humana Inc. merged, other major health insurers have also come under pressure to sign such deals. According to reports, next deal could be between Cigna Corp. and Anthem Inc. These insurers were said to be interested in buying Humana.
However, Humana was acquired by...read more
Results of the new Phase 3 study, called REACH-2, conducted by Eli Lilly and Co., showed that Cyramza therapy did not significantly improve overall survival in patients with advanced hepatocellular carcinoma (HCC) also known as liver cancer.
The liver cancer trial was conducted to see if...read more
A new study released on Friday establishes a link between a Merck immunotherapy drug named Keytruda and reduction in head and neck cancer which is the sixth most common cancer worldwide.
Keytruda, which is a drug that helps the immune system to fight cancer, was found to be twice as...read more
With the Federal Trade Commission (FTC) voting 5-0 to approve the settlement, a long running dispute over patent infringement is now fixed.
As part of the settlement, Teva which bought Cephalon in 2012 would pay $1.2 billion to repay ‘ill-gotten gains’ amassed by resorting to ‘pay-for-...read more
Amgen Inc's new cholesterol drug Repatha has received recommendation for approval in the European market. It is considered to be a big win among for Amgen, as it will put the company ahead in a race with rival Sanofi SA.
Repatha or evolocumab is a new class of cholesterol-reducing drugs...read more
With an aim to expand its generic business, Endo International (ENDP) announced that it will acquire Par Pharmaceutical Holdings. On Monday, Endo announced that it will pay $8.05 billion to private equity firm TPG to buy the company.
It will be a stock-and-cash deal, which has received...read more
The announcement of a new experimental drug, SAGE-547 by Sage Therapeutics Inc on Thursday, was welcomed by the investors. The company’s shares surged to $57.29, an upswing of about 57 percent since the beginning of the year.
After having tested the efficacy of its new drug on a patient...read more
On Tuesday, Baxter International Inc said that it has agreed to buy two drugs to treat a rare form of blood cancer from Italian drugmaker Sigma-Tau Finanziaria SpA for $900 million, before expenses.
Both the drugs are biologics for the treatment of acute lymphoblastic leukemia (ALL) and...read more
The U.S. Food and Drug Administration panel has granted fast track status to the cancer drug evofosfamide, being developed by Germany's Merck KGaA in collaboration with Threshold Pharmaceuticals.
Barry Selick, Chief Executive Officer of Threshold, stated, “We are pleased that...read more
Two months ago, AbbVie indicated towards its late-stage cancer drug venetoclax (ABT-199) as a prime reason behind its will to pay $21 billion in order to acquire Imbruvica-maker Pharmacyclics.
AbbVie said that the matching of the blood cancer blockbuster with its experimental therapy...read more
US-based biotech giant Gilead Sciences has acquired EpiTherapeutics of Denmark in $65 million deal.
As per the reports the purchase has given Gilead the rights to the Danish company's advanced small molecule inhibitors of enzymes, which are used in regulating the transcription of genes in...read more
Gilead Sciences successfully surpassed the expectations of Wall Street as the sales of its drugs to treat hepatitis C reached $4.55 billion in the first quarter. Gilead's new drug, Harvoni, which was approved in last October, had overall sales of $3.58 billion in this quarter.
But the...read more
The overall ‘asthma epidemic’ among children has...Read More
People in huge numbers gathered in the Mount Lofty...Read More
As New Year is approaching, people have already...Read More
Alzheimer’s disease, the commonest cause of...Read More
Cases of opioid abuse have been increasing and...Read More
In an announcement made on December 22, cable giant...Read More